Abstract
Pulmonary hypertension secondary to lung diseases, as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), is a relatively common condition with a bad prognosis. During the last World Congress in Nizza, detailed instructions about pulmonary hypertension secondary to lung diseases were provided. Long-term oxygen therapy is not able to normalize pulmonary artery pressure (PAP) values or to counteract vascular remodeling; the use of specific drug for pulmonary hypertension secondary to COPD or IPF, especially in severe forms, has often been suggested, but full indications have not yet been supplied.
| Translated title of the contribution | Pulmonary hypertension secondary to parenchimal lung diseases: Treatment perspectives |
|---|---|
| Original language | Italian |
| Pages (from-to) | 131-136 |
| Number of pages | 6 |
| Journal | Rassegna di Patologia dell'Apparato Respiratorio |
| Volume | 31 |
| Issue number | 3 |
| Publication status | Published - 2016 |
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Pulmonary and Respiratory Medicine